ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lebrikizumab

Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.

Drug pageLebrikizumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 28, 202544 company-led studies, 7 open or runningNext primary completion: Apr 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lillyits history only194 open or runningphase 4since May 28, 2025Feb 16, 2018May 2027phase 3 · NCT06338995
Hoffmann-La Roche180 open or runningphase 3since May 29, 2013Oct 27, 2008none ahead
Almirallits history only63 open or runningphase 3since Nov 26, 2021Nov 26, 2021Apr 25, 2027phase 3 · NCT06526182
Tanoxits history only10 open or runningphase 2since May 17, 2006May 17, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Oct 27, 2008.

  1. Aug 22, 2011Phase 1 study in Healthy VolunteerNCT01423318 · 60 enrolled · United States
  2. Mar 1, 20122 phase 2 studies in AsthmaNCT01545453, NCT01545440
  3. May 29, 20132 phase 3 studies in AsthmaNCT01867125, NCT01868061
  4. Jun 5, 2013Phase 2 study in Idiopathic Pulmonary FibrosisNCT01872689 · 505 enrolled · United States, Australia, Belgium and more
  5. Jun 7, 2013Phase 3 study in AsthmaNCT01875003 · 346 enrolled · United States, Argentina, Brazil and more
  6. Nov 12, 2013Phase 2 study in AsthmaNCT01987492 · 230 enrolled · United States, Australia, Belgium and more
  7. Mar 26, 2014Phase 3 study in AsthmaNCT02104674 · 313 enrolled · United States, Brazil, Bulgaria and more
  8. Mar 26, 2014Phase 2 study in AsthmaNCT02099656 · 64 enrolled · United States, Canada, France and more
  9. Jan 13, 2015Phase 2 study in Dermatitis, AtopicNCT02340234 · 212 enrolled · United States, Australia, Canada and more
  10. Jun 4, 2015Phase 2 study in Dermatitis, AtopicNCT02465606 · 55 enrolled · United States, Canada
  11. Jun 29, 2015Phase 1 study in Healthy VolunteerNCT02486809 · 176 enrolled · United States
  12. Sep 7, 2015Phase 3 study in AsthmaNCT02546869
  13. Sep 9, 2015Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT02546700 · 309 enrolled · United States, Argentina, Bulgaria and more
  14. Nov 10, 2026Phase 2 study terminatedStudy stoppedNCT01987492 · “Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.”

TargetBeta

IL13 →read by rule
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule

Other programs on IL13

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
zumilokibartAbbViephase 24
ompekimigPfizerphase 23
GHZ339Novartisphase 21
ABBV-313AbbViephase 11

Studies

All 18 Hoffmann-La Roche leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02546700Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more2CompletedNov 25, 2016309
NCT02546869Asthma3WithdrawnJun 29, 20160
NCT02486809Healthy Volunteer · United States1CompletedOct 2015176
NCT02465606Dermatitis, Atopic · United States, Canada2CompletedMay 30, 201655
NCT02340234Dermatitis, Atopic · United States, Australia, Canada and more2CompletedApr 2016212
NCT02104674Asthma · United States, Brazil, Bulgaria and more3CompletedJan 22, 2016313
NCT02099656Asthma · United States, Canada, France and more2CompletedOct 13, 201664
NCT01987492Asthma · United States, Australia, Belgium and more2TerminatedDec 19, 2016230
NCT01875003Asthma · United States, Argentina, Brazil and more3TerminatedDec 28, 2016346
NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more2CompletedJul 28, 2017505
NCT01868061Asthma · United States, Argentina, Australia and more3CompletedJan 2, 20171,068
NCT01867125Asthma · United States, Argentina, Australia and more3CompletedDec 28, 20161,081
NCT01545453Asthma · United States, Australia2CompletedJul 2013205
NCT01545440Asthma · United States, Australia2CompletedMar 2013258
NCT01423318Healthy Volunteer · United States1CompletedFeb 201260
NCT00971035Asthma2CompletedDec 2010210
NCT00930163Asthma2CompletedJul 2010218
NCT00781443Asthma2CompletedNov 200929

How it is read

Names in the registry

  • “Lebrikizumab”, 37 entries
  • “lebrikizumab”, 7 entries
  • “lebrikizumab (MILR1444A)”, 5 entries
  • “LY3650150”, 2 entries
  • “TNX-650”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.